ANTX

Over the past six months, AN2 Therapeutics, Inc.'s stock price saw a substantial increase of 394.96% from September 8, 2025, to September 4, 2026. The company participated in several healthcare conferences, including Leerink, Stifel, and Jefferies. On August 11, 2026, AN2 Therapeutics reported its second-quarter 2026 financial results and highlighted business and scientific achievements, including expanding Phase 2 study activities for epetraborole in polycythemia vera. Cameron Trenor, M.D., was appointed Chief Medical Officer on August 24, 2026. Clinical data supporting the development of epetraborole for polycythemia vera was presented at the SOHO 2026 Annual Meeting on August 31, 2026. On September 9, 2026, a director sold shares totaling $6,674, and inducement grants were reported on September 16, 2026. Epetraborole failed to show sufficient efficacy in a Phase 2/3 clinical trial for treatment-refractory Mycobacterium avium complex (MAC) lung disease, which negatively impacted the company's valuation, though its observed red-cell reductions are now being explored for polycythemia vera. Guggenheim initiated coverage on AN2 Therapeutics with a 'buy' rating and a price target of $9.00, citing epetraborole's potential.